Prophylaxis of HIV Infection following Occupational Exposure
Tóm tắt
To review the risk of HIV infection following occupational exposure, the theoretical basis for chemoprophylaxis, investigative experience with chemoprophylaxis in animals and humans, and the economic aspects of postexposure chemoprophylaxis.
English-language articles and conference proceedings pertaining to the risk of occupational HIV infection and to postexposure chemoprophylaxis.
Studies evaluating chemoprophylaxis of HIV infection following occupational exposure were selected for review. Abstracts reporting ongoing clinical trials were also included.
In vitro studies are discussed to provide the immunologic rationale for chemoprophylaxis. Animal studies examining the efficacy of chemoprophylaxis in preventing non-HIV retroviral infection are reviewed, and their applicability to human HIV infection is critically evaluated. Human studies and case reports describing attempts at chemoprophylaxis of HIV infection following occupational exposure are discussed.
Chemoprophylaxis of HIV infection following occupational exposure has focused on the use of zidovudine (ZDV) because it was previously the only antiretroviral agent approved for treating HIV infection. Animal models of retroviral infection provide conflicting data regarding the efficacy of ZDV chemoprophylaxis, and there are important questions about the applicability of animal data to human HIV infection because of differences in natural histories of non-HIV retroviral infections, inoculum size, dosing of ZDV, and routes of infection. Human surveillance studies are thus far inadequate to determine the efficacy of ZDV prophylaxis because of the very low HIV seroconversion rates following occupational exposure. ZDV is well tolerated during short-term administration in people without HIV infection, but long-term safety is unknown. In addition, the true cost-benefit ratio of ZDV chemoprophylaxis is uncertain.
Current data from in vitro, animal, and human studies are inadequate to define the appropriate role of ZDV in preventing HIV infection following occupational exposure. Limited toxicity data and the high cost of treatment must be weighed against the theoretical benefits of ZDV use in this setting. The decision to employ ZDV for postexposure prophylaxis must ultimately be based on existing institutional policies, the attitude of the responsible physician regarding such practice, and/or the desires of the exposed healthcare worker after being properly informed of potential risks and benefits.
Từ khóa
Tài liệu tham khảo
1984, Lancet, 2, 1376
Centers for Disease Control, 1990, MMWR, 39, 1
Henry K, 1992, Int Conf AIDS, 8, C269
Battan R, Raviglione MC, Cortes H, Sugar J, Garner G, Raviglione NC. Risk of exposure to HIV-infected body fluids among medical housestaff (MHS) (abstract 957). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 245.
Gerberding JL, Littell C, Brown A, Raniro N. Cumulative risk of HIV and hepatitis B (HBV) among health care workers (HCW): longterm serologic followup and gene amplification for latent HIV infection (abstract 959). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.
Fahey BJ, Beekmann SE, Schmitt J, Fedio J, Henderson DK. Assessment of risk for occupational HIV-l infection in health care workers (HCW) and safety of zidovudine (AZT) administered as postexposure chemoprophylaxis for occupational exposures (abstract 960). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.
Marcus R, Tokars JI, Culver DH, McKibben PS, Bell DM. Zidovudine use after occupational exposure to HIV-infected blood (abstract 979). Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 262.
Centers for Disease Control, 1988, MMWR, 37, 377
Centers for Disease Control, 1989, MMWR, 38, S1
Kneer C, Sinnott J, Shaw K. Percutaneous and mucocutaneous exposure of third year medical students to blood and blood-tinged body fluids (abstract 972). Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 261.
Tokars JI, Marcus R, Culver DH, Bell DM. Blood contacts during surgical procedures (SPs) (abstract 958). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.
Gerberding JL, Wugofsky L, Berkvan G, Mangione C, Rinaldi J, Guokas E, Facilitated surveillance and post-exposure AZT prophylaxis for health care workers (HCW): the San Francisco General Hospital model (abstract 961). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.
Ramsey KM, 1988, Clin Res, 36, 22A
Wormser GP, 1988, Bull N Y Acad Med, 64, 203
Henderson DK, 1990, Principles and practice of infectious diseases, 3, 2221
Centers for Disease Control, 1988, MMWR, 37, 229
Centers for Disease Control, 1987, MMWR, 36, 1
Centers for Disease Control, 1987, MMWR, 36, 285
Tokars JI, Marcus RA, Culver DH, McKibben PS, Bell DM. Zidovudine (AZT) use after occupational exposure to HIV-infected blood (abstract 490). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 168.
Hessol NA, 1990, J Acquir Immune Defic Syndr, 3, 1078
Fletcher CV, 1991, Clin Pharmacol Ther, 49, 198
Tavares L, 1987, Cancer Res, 47, 3190
Schinazi RF, Anderson DC, Fultz P, McClure HM. Prophylaxis with antiretroviral agents in rhesus macaques inoculated with simian immunodeficiency virus (abstract 962). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.
Gerberding JL, Marx P, Gould R, Joye S, Lackner A. Simian model of retrovirus chemoprophylaxis with constant infusion zidovudine ± interferon alpha (abstract 976). Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 261.
Reitz MS, 1990, Principles and practice of infectious diseases, 3, 1344
Gerberding JL, Fahrner R, Berkvan G, Thibault K. Zidovudine post-exposure chemoprophylaxis for health care workers exposed to HIV at San Francisco General (abstract 977). Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 262.
LaFon SW, Mooney BD, McMullen JP, Pattishall KH, Smiley ML, Rogers MD, A double-blind, placebo-controlled study of the safety and efficacy of Retrovir (zidovudine, ZDV) as a chemoprophy-lactic agent in health care workers (HCW) exposed to HIV (abstract 489). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 167.
Payne SF, Lemp GF, Rutherford GW. Survival following AIDS-related opportunistic infections in San Francisco (abstract 1249). Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 23–26, 1988. Washington, DC: American Society for Microbiology, 1988: 332.
Rhame FS, 1991, N Engl J Med, 324, 1266
Erice A, Strike DG, Sannerud KJ, Balfour HHJr. Zidovudine (ZDV) susceptibilities of human immunodeficiency virus type l (HIV-l) isolates from patients with acute HIV-l infection treated with ZDV (abstract 569). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 205.
Erice A, Mayers DL, Sannerud KJ, Fischl MA, Balfour HHJr. Zidovudine (ZDV) susceptibilities and genotypic characterization of HIV-l isolates from symptomatic patients with 200–800 CD4+ cells/mm3 (abstract 576). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 206.
Principi N, Vago T, Massironi E, Tornaghi R, de Pasquale MP, Marchisio P. HIV-l reverse transcriptase mutations in children treated with zidovudine (abstract 570). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 205.
Fitzgibbon J, Farnham A, Sperber S, Mazar S, Dubin D. AZT and ddC resistance mutations in HIV from a patient treated with both agents (abstract 574). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 206.
Husson R, Shirasaka T, Butler K, Pizzo P, Mitsuya H. High level resistance to AZT, but not to ddC or ddI in HIV from children receiving long-term antiretroviral therapy (abstract 571). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 206.
Shirasaka T, 1992, Int Conf AIDS, 8, B182
McLeod GX, McGrath JM, Connolly KJ, Allan JD, Hammer SM. Dideoxyinosine (ddI) and zidovudine (AZT) resistance patterns in clinical isolates of HIV-1 (abstract 1355). Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 325.